Background: Growth arrest specific 5 (GAS5) is a long noncoding RNA (lncRNA) that regulates the function of cardiovascular cells in various cardiovascular diseases. The current study delved into the regulation of GAS5 on the function of endothelial progenitor cells (EPCs) and its potential regulatory mechanism in coronary heart disease (CHD).
Methods: Reverse transcription-quantitative polymerase chain reaction was used to detect GAS5 expression in the blood samples and EPCs from CHD patients and healthy controls. Cell Counting Kit-8, colony formation, flow cytometry, and transwell assays were performed to evaluate cell phenotype of EPCs. Ferroptosis was detected by the measurement of Fe2+, malondialdehyde, GSH, and reactive oxygen species (ROS) levels. Glycolysis was determined by extracellular acidification rate (ECAR), oxygen consumption rate (OCR), glucose uptake and lactate production.
Results: Growth arrest specific 5 was downregulated in the blood samples and EPCs from CHD patients. Growth arrest specific 5 deficiency suppressed EPC proliferative capacity, migration, invasion and facilitated EPC apoptosis while GAS5 overexpression showed contrary effects. Moreover, GAS5 silencing inhibited the glucose metabolic reprogramming, as evidenced by the reduced ECAR, glycolysis capacity, ATP, glucose uptake and lactate production, and elevated OCR. Additionally, GAS5 overexpression attenuated the erastin-induced ferroptosis of EPCs. Growth arrest specific 5 could bind to IGF2BP1 to enhance the mRNA stability of glycolysis transcriptional regulator SIX1. Growth arrest specific 5 interacted with miR-23a-3p to regulate SLC7A11 expression. GAS5 promoted glucose metabolic reprogramming of EPCs by upregulating SIX1 and inhibited EPC ferroptosis by elevating SLC7A11.
Conclusion: Growth arrest specific 5 promotes glucose metabolic reprogramming and represses ferroptosis of EPCs via the IGF2BP1/SIX1 and miR-23a-3p/SLC7A11 dual-regulatory pathways in CHD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14744/AnatolJCardiol.2025.5042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PRR11 Promotes Bladder Cancer Growth and Metastasis by Facilitating G1/S Progression and Epithelial-Mesenchymal Transition.
Cancer Med
March 2025
Department of Urology, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Background: Although Proline-rich Protein 11 (PRR11) abnormalities are closely associated with carcinogenesis, the precise mechanism of bladder cancer remains unclear. Here, we sought to elucidate the molecular mechanisms of PRR11 in bladder cancer.
Methods: We performed differential expression analysis of PRR11 from the TCGA and GEO databases, followed by validation with clinical samples.
LncRNA Growth Arrest Specific 5 Promotes Glucose Metabolism Reprogramming Via the IGF2BP1/SIX1 Axis and Inhibits Ferroptosis of Endothelial Progenitor Cells Via the miR-23a-3p/SLC7A11 Axis in Coronary Heart Disease.
Anatol J Cardiol
March 2025
Department of Cardiology, Heart Center, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China.
Background: Growth arrest specific 5 (GAS5) is a long noncoding RNA (lncRNA) that regulates the function of cardiovascular cells in various cardiovascular diseases. The current study delved into the regulation of GAS5 on the function of endothelial progenitor cells (EPCs) and its potential regulatory mechanism in coronary heart disease (CHD).
Methods: Reverse transcription-quantitative polymerase chain reaction was used to detect GAS5 expression in the blood samples and EPCs from CHD patients and healthy controls.
Ubiquitin specific protease 7 is a potential therapeutic target for gastric cancer.
Front Oncol
February 2025
Department of Pathology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, China.
Introduction: As a deubiquitinase, ubiquitin-specific protease 7 (USP7) plays a vital role in diverse cancers, nevertheless, its role in gastric cancer (GC), which is the fifth leading cause of death in diverse cancers worldwide, has rarely been reported.
Methods: To gain a comprehensive understanding about USP7 in the progression of GC, 287 paired GC tissues were collected and analyzed. ShRNA and small molecular inhibitor were used to investigate the impact of USP7 on cell proliferation.
Wearable photobiomodulation halts thyroid cancer growth by leveraging thyroid photosensitivity.
Bioeng Transl Med
March 2025
Department of Endocrinology Nanjing Drum Tower Hospital, School of Life Science and Technology, China Pharmaceutical University Nanjing China.
With papillary thyroid carcinoma (PTC) rates rising significantly, concerns about conventional treatments like thyroidectomy and radiotherapy highlight the need for non-invasive options. Our study explores photobiomodulation therapy (PBMT), which uses specific light wavelengths to evoke cellular responses in PTC treatment. Our research utilized a custom-designed optical system to investigate PBMT, finding that blue light at a wavelength of 465 nm can safely and effectively inhibit the proliferation of the TPC-1 PTC cell line by inducing cell cycle arrest.
View Article and Find Full Text PDFUnlabelled: Highly multiplexed imaging assays allow simultaneous quantification of multiple protein and phosphorylation markers, providing a static snapshots of cell types and states. Pseudo-time techniques can transform these static snapshots of unsynchronized cells into dynamic trajectories, enabling the study of dynamic processes such as development trajectories and the cell cycle. Such ordering also enables training of mathematical models on these data, but technical challenges have hitherto made it difficult to integrate multiple experimental conditions, limiting the predictive power and insights these models can generate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!